10% Discount on Japan Pharma (Valid Till 7th June 2016)

April 09th 2016 Mumbai, India: Bharatbook.com announces a report on “ Japan Pharma Outlook 2016 : JP Giants leaning in for becoming a Speciality Global Pharma ”. The biennial price cut scheduled in April-2016 will balance Innovation premium with long listed price cut (Z2 rule) to increase R & D productivity.

"Sakigake designation – A Push from government to “Innovate”!

“Essential drugs” exemption from Z2 rule- Balancing long listed pricing pressure!

Authorized Generics, Biosimilars, and Patent Litigations - Avenues to grow in JP Generic market!

Increasing decline in long listed products sales, and a few success in R & D in the last decade had put JP giants under pressure to refocus on Innovation with specialty therapy area to strengthen their global presence. https://www.bharatbook.com/healthcare-market-research-reports-391753/japan-pharma-jp-giants-leaning-speciality.html Eisai Ajinomoto JV, Teva-Takeda partnership for Speciality Generics is the actions in this direction. Fast track approval based on “Sakigake” designation is the step by PMDA/MHLW to encourage JP Pharmas to research in the area of high unmet medical need/orphan disease where US biotech has taken a successful leap in last decade.

In innovation space, Nivolumab, Alectinib, Dolutegravir global success again demonstrate ability of JP pharma/university research house to contribute Pharma Innovation, while encouraging regulatory environment for “Regenerative Medicine Drug Development” and “Drug Repurposing” will make Japan front runner in this space. From late stage pipeline/new launch, Mirogabalin approval in Neuropathic Pain, Brintellix Cognition label expansion, Edoxaban uptake in EU, Alectinib uptake in US and ACE-910 approval for hemophilia will decide Japanese Innovator growth in Global market. The biennial price cut scheduled in April-2016 will balance Innovation premium with long listed price cut (Z2 rule) to increase R & D productivity.

In next 3 years, ¥950b drugs will...